Corvert Related Published Studies
Well-designed clinical trials related to Corvert (Ibutilide)
Propafenone added to ibutilide increases conversion rates of persistent atrial fibrillation. [2006.05]
Is pretreatment with ibutilide useful for atrial fibrillation cardioversion when combined with biphasic shock? [2006.02]
Comparison of intravenous ibutilide vs. propafenone for rapid termination of recent onset atrial fibrillation. [2005.12]
The combined use of ibutilide as an active control with intensive electrocardiographic sampling and signal averaging as a sensitive method to assess the effects of tadalafil on the human QT interval. [2005.08.16]
[Immediate cardioversion of atrial fibrillation and atrial flutter lasting less than 90 days by ibutilide versus propafenone: a multicenter study] [2005.03.30]
Clinical comparison of ibutilide and propafenone for converting atrial flutter. [2005.01]
Well-designed clinical trials possibly related to Corvert (Ibutilide)
An evaluation of the impact of oral magnesium lactate on the corrected QT interval of patients receiving sotalol or dofetilide to prevent atrial or ventricular tachyarrhythmia recurrence. [2006.04]
Other research related to Corvert (Ibutilide)
Intravenous magnesium sulfate enhances the ability of intravenous ibutilide to successfully convert atrial fibrillation or flutter. [2007.11]
Pharmacokinetic and pharmacodynamic properties of a single intravenous dose of ibutilide fumarate: a phase I, randomized, open-label, increasing-dose study in healthy chinese men. [2007.09]
The safety and efficacy of ibutilide in children and in patients with congenital heart disease. [2007.08]
Enhancement of bupivacaine local anesthesia with the potassium channel blocker ibutilide. [2007.07]
Conversion efficacy of intravenous ibutilide compared with intravenous amiodarone in patients with recent-onset atrial fibrillation and atrial flutter. [2007.06.12]
Ibutilide-induced cardioversion of atrial fibrillation during pregnancy. [2007.05]
Successful termination of atrial flutter by ibutilide during pregnancy. [2007.02]
The role of amiodarone in recent-onset atrial fibrillation after ibutilide has failed to restore sinus rhythm. [2007]
Conversion efficacy of intravenous ibutilide compared with intravenous amiodarone in patients with recent-onset atrial fibrillation and atrial flutter. [2006.10.16]
Ibutilide to expedite ED therapy for recent-onset atrial fibrillation flutter. [2006.07]
Efficacy and safety of ibutilide for the conversion of monomorphic atrial tachycardia. [2006.04]
Ibutilide for treatment of atrial fibrillation in the emergency department. [2006.02]
High-density mapping of pulmonary veins and left atrium during ibutilide administration in a canine model of sustained atrial fibrillation. [2005.12]
Rapid cardioversion of new onset atrial fibrillation with ibutilide in the emergency department. [2005.09]
Efficacy and safety of ibutilide for cardioversion of atrial flutter and fibrillation in patients receiving amiodarone or propafenone. [2005.09]
Conversion of recent-onset atrial fibrillation or flutter with amiodarone after ibutilide has failed: a rapid, efficient, and safe algorithm. [2005.07]
Ibutilide--recent molecular insights and accumulating evidence for use in atrial flutter and fibrillation. [2005.05]
Ibutilide in persistent atrial fibrillation refractory to conventional cardioversion methods. [2005.03.18]
Ibutilide for rapid conversion of atrial fibrillation or flutter in a mixed critically ill patient population. [2005.02]
Other possibly related research studies
Bazett and Fridericia QT correction formulas interfere with measurement of drug-induced changes in QT interval. [2006.09]
[Inhibition of the muscarinic potassium current by KB130015, a new antiarrhythmic agent to treat atrial fibrillation] [2005.11.15]
[Atrial flutter and fibrillation] [2005.11.09]
Consequences of atrial electrical remodeling for the anti-arrhythmic action of class IC and class III drugs. [2005.07.01]
Comparative efficacy of monophasic and biphasic waveforms for transthoracic cardioversion of atrial fibrillation and atrial flutter. [2005.02]
Pharmacological treatment of atrial fibrillation: mechanisms of action and efficacy of class III drugs. [2006]
Pharmacological management of atrial fibrillation following cardiac surgery. [2005]
Short QT syndrome. Genotype-phenotype correlations. [2005.10]
Enhancing electrical cardioversion and preventing immediate reinitiation of hemodynamically deleterious atrial fibrillation with class III drug pretreatment. [2005.07]
Short QT syndrome. [2005.08.15]
[Safety of new anti-arrhythmic drugs] [2005.04]
Autonomic tone attenuates drug-induced QT prolongation. [2007.08]
Cardioversion of persistent atrial fibrillation by a combination of atrial specific and non-specific class III drugs in the goat. [2007.07.01]
Monotherapy versus combination therapy with class III antiarrhythmic agents to attenuate transmural dispersion of repolarization: a potential risk factor for torsade de pointes. [2007.09]
Autonomic tone attenuates drug-induced QT prolongation. [2007.09]
Effect of drugs on defibrillation capacity. [2008]
Characterization of transient atrial rhythm occurring between typical atrial flutter and its termination with class III drugs. [2008.08]
Relationship among amiodarone, new class III antiarrhythmics, miscellaneous agents and acquired long QT syndrome. [2008]
|
